Literature DB >> 9862874

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

M Prieto1, M Berenguer, J M Rayón, J Córdoba, L Argüello, D Carrasco, A García-Herola, V Olaso, M De Juan, M Gobernado, J Mir, J Berenguer.   

Abstract

The natural history of hepatitis C virus (HCV) infection following liver transplantation and predictors of disease severity remain controversial. The aims of the study were to assess in a homogeneous population of 81 cyclosporine-based HCV-infected liver transplant recipients mostly infected with genotype 1b and undergoing strict protocol annual biopsies: 1) the histological progression of posttransplantation HCV disease and, in particular, the incidence of HCV-related graft cirrhosis within the first 5 years after surgery; and 2) the relationship between progression to cirrhosis and i) rejection episodes and ii) first-year liver biopsy findings. We studied 81 consecutive HCV-RNA-positive patients (96% genotype 1b) undergoing liver transplantation between 1991 and 1996 with a minimum histological follow-up of 1 year. All patients received cyclosporine-based immunosuppression and underwent protocol yearly liver biopsies for the first 5 years. The mean histological follow-up was 32 months (range, 12-60 months). Biopsies were scored according to the histological activity index (HAI), with separate evaluation of grade (activity) and stage (fibrosis). Histological hepatitis, present in 97% of patients in the most recent biopsy, was moderate or severe in 64%. Twelve patients developed HCV-related cirrhosis at a median time of 24 months (range, 12-48 months), with an actuarial rate of HCV-cirrhosis of 3.7%, 8.5%, 16%, 28%, and 28% at 1, 2, 3, 4, and 5 years, respectively. Rejection was significantly more common among patients with cirrhosis versus those without (83% vs. 48%; P =.02), with an association between the incidence of cirrhosis and the number of rejection episodes: 5%, 15%, and 50% in patients without rejection, one and two episodes, respectively (P =.001). The degree of activity and fibrosis score in the first-year biopsy were higher in patients who developed cirrhosis than in those who did not (P =.008 and.18, respectively). In conclusion, HCV genotype 1b-infected liver recipients are at a high risk of developing graft cirrhosis in the first 4 to 5 years following transplantation, especially those with previous rejection episodes. First-year liver biopsies may help to sooner identify patients at the highest risk, improving further patient management.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9862874     DOI: 10.1002/hep.510290122

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  67 in total

Review 1.  Hepatitis C and liver transplantation.

Authors:  M Berenguer; T L Wright
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

Review 2.  Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.

Authors:  Kymberly D S Watt; Kelly Burak; Marc Deschênes; Les Lilly; Denis Marleau; Paul Marotta; Andrew Mason; Kevork M Peltekian; Eberhard L Renner; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

3.  Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection.

Authors:  Mark W Russo; Tarun Narang; Lon Eskind; Daniel Hayes; Vincent Casingal; Preston P Purdum; John S Hanson; Will Ahrens; James Norton; Herbert Bonkovsky
Journal:  Dig Dis Sci       Date:  2013-06-29       Impact factor: 3.199

Review 4.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 5.  Living donor liver transplantation to patients with hepatitis C virus cirrhosis.

Authors:  Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 6.  Hepatitis C virus-HIV-coinfected patients and liver transplantation.

Authors:  Ani A Kardashian; Jennifer C Price
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

7.  Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution.

Authors:  Ashwin Balagopal; Stuart C Ray; Ruben Montes De Oca; Catherine G Sutcliffe; Perumal Vivekanandan; Yvonne Higgins; Shruti H Mehta; Richard D Moore; Mark S Sulkowski; David L Thomas; Michael S Torbenson
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

Review 8.  Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.

Authors:  Jan Peveling-Oberhag; Stefan Zeuzem; Wolf Peter Hofmann
Journal:  Med Microbiol Immunol       Date:  2009-11-10       Impact factor: 3.402

9.  Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis.

Authors:  Perdita Wietzke-Braun; Felix Braun; Burckhart Sattler; Giuliano Ramadori; Burckhardt Ringe
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

10.  A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.

Authors:  James R Burton; Jacqueline G O'Leary; Elizabeth C Verna; Varun Saxena; Jennifer L Dodge; Richard T Stravitz; Joshua Levitsky; James F Trotter; Gregory T Everson; Robert S Brown; Norah A Terrault
Journal:  J Hepatol       Date:  2014-05-05       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.